רווח לפני ניכוי ריבית, מסים, בלאי ופחת: paysign.com (PAYS)

Paysign, Inc. (PAYS) dominates the niche plasma donor payment segment, possessing significant pricing power. The EBITDA growth trajectory clearly confirms the effectiveness of this model, where the current value equals 26.36. The company's environmental focus is implemented through account virtualization, while its development strategy relies exclusively on internal fintech innovations without the use of external acquisitions.

The scaling of medical processing at Paysign, Inc. (PAYS) with minimal CAPEX generates a stable inflow of liquidity, which is directly reflected in the cash EBITDA trend. This indicator measures the business's actual ability to maintain operating cash flow during periods of macroeconomic turbulence, allowing investors to identify a weakening of fundamental positions in a timely manner and avoid capital freezes amid rising Fed rates.